{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 44 of 129', '32. Employees of the trial site or any other individuals directly involved with the planning', 'or conduct of the trial or immediate family members of such individuals.', '8.4 Enrolment', 'Trial participation begins once written informed consent is obtained (see Appendix 3B for', 'details on the informed consent process). Once informed consent is obtained, a subject', 'identification number (subject ID) will be assigned by a central IWRS and the screening', 'evaluations to assess eligibility criteria may begin. The subject ID will be used to identify the', 'subject during the screening process and throughout trial participation, if applicable. A master', 'log of all consented subjects will be maintained at the trial site.', 'Screening failures are defined as subjects who consent to participate in the trial but are not', 'subsequently randomly assigned to trial treatment. A minimal set of screening failure', 'information is required to ensure transparent reporting of screening failure subjects to meet', 'the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements (22)', 'and to respond to queries from regulatory authorities. Minimal information includes', 'demography, screening failure details, eligibility criteria, and reporting of any AEs and serious', 'AEs (SAEs). Follow-up of SAEs must be carried out according to Section 11.6.', 'Individuals who do not meet the criteria for participation in this trial (screening failures) may', 'not be re-screened. However, if the reason for screening failure is administrative and not due', 'to the subject failing to meet the eligibility criteria, re-screening may be permitted (this will', \"require approval by the sponsor's medical expert after thorough review of all data from the\", 'original screening visit in the electronic case report form [eCRF]). Individuals who are', 're-screened will get a new subject ID.', 'The investigator will maintain a list of all randomised subjects at the trial site including each', \"subject's identity, date of informed consent, and corresponding subject ID so that any subject\", 'may be identified if required for any reason. The list must not be copied or retained by LEO.', '8.5 Discontinuation', 'A subject may withdraw from trial or from treatment at any time (prior to first dose or during', 'the treatment period) at his/her own request. A subject may be withdrawn at any time at the', 'discretion of the investigator. Discontinued subjects will not be replaced.', 'Medical reasons for permanent discontinuation of IMP are given in Section 9.7.1.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 45 of 129', 'Subjects who permanently discontinue IMP for any reason will be asked to attend an early', 'termination visit and return to the trial site for 1 or 2 additional visits as indicated below', 'depending on the time of discontinuation of IMP (see the schedule of procedures [Panel 3] for', 'data to be collected at these visits). The investigator will review any AEs which will be', 'followed-up according to Section 11.6, if the subject agrees.', 'Subjects who permanently discontinue IMP prior to Week 16 will be asked to attend:', 'Early termination visit.', 'Nominal Week 16 visit (16 weeks after randomisation).', 'Safety follow-up visit (16 weeks after last administration of IMP).', 'Subjects who permanently discontinue IMP at Week 16 or after Week 16 will be asked to', 'attend:', 'Early termination visit.', 'Safety follow-up visit (16 weeks after last administration of IMP).', 'If a subject withdraws from the trial, he/she may request destruction of any samples taken and', \"not tested, and the investigator must document this in the site's trial records.\", 'Reason(s) for discontinuation from IMP and withdrawal from the trial must be recorded in the', 'medical records and the eCRF (lack of efficacy, AE, withdrawal by subject, lost to follow-up,', 'death, other). For subjects randomised to IMP but not attending any post-baseline visits, it', 'will be recorded whether any safety evaluations were performed after exposure to IMP.', 'Lost to follow-up', 'A subject will be considered lost to follow-up if they repeatedly fail to return for scheduled', 'visits and if the trial site is not able to get in contact with the subject.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}